Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole dosing in children and adolescents with cystic fibrosis and Aspergillus infection
2019-004511-31Phase 2
- Sponsor
- Ospedale Pediatrico Bambino Gesù
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of posaconazole in cystic fibrosis (CF) and aspergillosis, sponsored by Ospedale Pediatrico Bambino Gesù. Primary endpoint: Primary pharmacokinetic endpoint.
02
Drugs
posaconazole
03
Conditions
cystic fibrosis (CF)aspergillosis
Beyond the preview
Go deeper on 2019-004511-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004511-31.